CAR-T cells overexpressing GLUT1 or AGK have demonstrated potent antitumor effects, suggesting that combining CAR-T therapy with ICB could further enhance the metabolic activity of CD8+ T cells and improve treatment outcomes in HCC[125]. This evidence concerns the gene SLC2A1 and hepatocellular carcinoma.